Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:02:52.300Z.
Calculation as of: 2026-10-06T18:02:52.300Z.
Quote observation: 2026-10-06T17:58:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fc2e94c8beea8e322b310e9b25a1b89028fd55b2fc6a2790cf1d230843e32158
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Incannex Healthcare Limited
Market Cap
$37.75M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$36.94M
EV/Sales Ratio
N/A
TTM Avg
59371.36x
3Y Avg
19906.10x
5Y Avg
11981.70x
Market Cap
$38.88M
EV/Sales Ratio
0.87x
TTM Avg
0.74x
3Y Avg
1.17x
5Y Avg
1.52x
Market Cap
$39.15M
EV/Sales Ratio
2.79x
TTM Avg
2.62x
3Y Avg
2.78x
5Y Avg
2.78x
Market Cap
$36.28M
EV/Sales Ratio
1.05x
TTM Avg
7.17x
3Y Avg
30.29x
5Y Avg
30.29x
Market Cap
$35.69M
EV/Sales Ratio
3.21x
TTM Avg
7.33x
3Y Avg
18.71x
5Y Avg
16.11x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incannex Healthcare Limited (IXHL) | $37.75M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $36.94M | N/A | 59371.36x | 19906.10x | 11981.70x |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.88M | 0.87x | 0.74x | 1.17x | 1.52x |
| Nephros, Inc. (NEPH)vs › | $37.67M | 1.63x | 2.22x | 1.81x | 1.98x |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.15M | 2.79x | 2.62x | 2.78x | 2.78x |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | 1.05x | 7.17x | 30.29x | 30.29x |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.23M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.81M | 0.12x | 0.15x | 0.42x | 1.17x |
| EUDA Health Holdings Limited (EUDA)vs › | $35.69M | 3.21x | 7.33x | 18.71x | 16.11x |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.34M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
